CRPC consists of multiple molecular and histologic subtypes of prostate cancer including neuroendocrine prostate cancer (NEPC) which takes on characteristics of neuroendocrine (NE) differentiation and is no longer responsive to AR-directed treatments. This evidence concerns the gene AR and prostate carcinoma.